Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Siponimod

FDA-approved product (tablet, oral), marketed as Mayzent, Siponimod.

Registered studies
33
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Siponimod
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Multiple sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sphingosine-1-phosphate (s1p) receptor modulators
FDA pharmacologic class
Sphingosine 1-phosphate Receptor Modulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Siponimod in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Siponimod with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

    NCT04593927 · start 2020-10-28

    Registered record
    Registry ID
    NCT04593927
    Conditions
    Secondary Progressive Multiple Sclerosis (SPMS)
    Interventions
    Mayzent
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-10-28
    Completion
    2023-08-30
    Enrolment
    451

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis (SPMS)
    InterventionMayzent
    PhaseNot recorded
    Registry statusCompleted

  • Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo

    NCT05826028 · start 2020-07-09

    Registered record
    Registry ID
    NCT05826028
    Conditions
    Secondary Progressive Multiple Sclerosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-09
    Completion
    2022-04-20
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

    NCT03623243 · start 2019-02-14

    Registered record
    Registry ID
    NCT03623243
    Conditions
    Multiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple Sclerosis
    Interventions
    Siponimod
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-02-14
    Completion
    2022-07-06
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Relapsing Multiple Sclerosis; Advancing Multiple Sclerosis
    InterventionSiponimod
    PhasePhase 3
    Registry statusCompleted

  • Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

    NCT03535298 · start 2019-01-03

    Registered record
    Registry ID
    NCT03535298
    Conditions
    Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Early Highly Effective Therapies Group; Escalation Therapies Group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2019-01-03
    Completion
    2027-07-30
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis, Relapsing-Remitting
    InterventionEarly Highly Effective Therapies Group; Escalation Therapies Group
    PhasePhase 4
    Registry statusActive not recruiting

  • Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

    NCT03500328 · start 2018-05-02

    Registered record
    Registry ID
    NCT03500328
    Conditions
    Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2018-05-02
    Completion
    2026-09
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis, Relapsing-Remitting
    InterventionNatalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
    PhaseNot applicable
    Registry statusActive not recruiting

  • Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

    NCT03338998 · start 2017-12-24

    Registered record
    Registry ID
    NCT03338998
    Conditions
    Hemorrhagic Stroke; Intracerebral Hemorrhage (ICH)
    Interventions
    BAF312 solution; Matching Placebo for BAF312 solution; BAF312 tablet; Matching Placebo for BAF312 tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-12-24
    Completion
    2020-05-13
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemorrhagic Stroke; Intracerebral Hemorrhage (ICH)
    InterventionBAF312 solution; Matching Placebo for BAF312 solution; BAF312 tablet; Matching Placebo for BAF312 tablet
    PhasePhase 2
    Registry statusCompleted

  • Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

    NCT02330965 · start 2014-12

    Registered record
    Registry ID
    NCT02330965
    Conditions
    Secondary Progressive Multiple Sclerosis
    Interventions
    Blood Draw; CSF collection by lumbar puncture (Optional)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-12
    Completion
    2017-07-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis
    InterventionBlood Draw; CSF collection by lumbar puncture (Optional)
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of BAF312 in Dermatomyositis

    NCT02029274 · start 2013-08-25

    Registered record
    Registry ID
    NCT02029274
    Conditions
    Active Dermatomyositis
    Interventions
    BAF312; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-08-25
    Completion
    2016-02-17
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActive Dermatomyositis
    InterventionBAF312; Placebo
    PhasePhase 2
    Registry statusTerminated

  • A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

    NCT01904214 · start 2013-07

    Registered record
    Registry ID
    NCT01904214
    Conditions
    Renal Impairment
    Interventions
    BAF312
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionBAF312
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Tolerability of BAF312 in Patients With Polymyositis

    NCT01801917 · start 2013-04-24

    Registered record
    Registry ID
    NCT01801917
    Conditions
    Polymyositis
    Interventions
    Placebo; BAF312
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-04-24
    Completion
    2016-08-05
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolymyositis
    InterventionPlacebo; BAF312
    PhasePhase 2
    Registry statusTerminated

  • Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

    NCT01665144 · start 2012-12-20

    Registered record
    Registry ID
    NCT01665144
    Conditions
    Secondary Progressive Multiple Sclerosis
    Interventions
    BAF312; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-12-20
    Completion
    2023-03-31
    Enrolment
    1,651

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Progressive Multiple Sclerosis
    InterventionBAF312; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

    NCT01565902 · start 2012-10

    Registered record
    Registry ID
    NCT01565902
    Conditions
    Hepatic Impairment
    Interventions
    BAF312
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionBAF312
    PhasePhase 1
    Registry statusCompleted

  • Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

    NCT01185821 · start 2010-08-30

    Registered record
    Registry ID
    NCT01185821
    Conditions
    Relapsing Remitting Multiple Sclerosis
    Interventions
    BAF312
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-08-30
    Completion
    2016-10-10
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsing Remitting Multiple Sclerosis
    InterventionBAF312
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

    NCT01148810 · start 2010-06-15

    Registered record
    Registry ID
    NCT01148810
    Conditions
    Polymyositis; Dermatomyositis
    Interventions
    BAF312; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-06-15
    Completion
    2012-06-13
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolymyositis; Dermatomyositis
    InterventionBAF312; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

    NCT00879658 · start 2009-03-30

    Registered record
    Registry ID
    NCT00879658
    Conditions
    Relapsing-remitting Multiple Sclerosis
    Interventions
    BAF312; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03-30
    Completion
    2011-05-04
    Enrolment
    297

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsing-remitting Multiple Sclerosis
    InterventionBAF312; Placebo
    PhasePhase 2
    Registry statusCompleted